177 related articles for article (PubMed ID: 17080767)
1. Application of an adaptive design to a randomized phase II selection trial in gastric cancer: a report of the study design.
Morita S; Sakamoto J
Pharm Stat; 2006; 5(2):109-18. PubMed ID: 17080767
[TBL] [Abstract][Full Text] [Related]
2. Comments on 'Application of an adaptive design to a randomized phase II selection trial in gastric cancer: a report of the study design' by Satoshi Morita and Junichi Sakamoto. Pharmaceutical Statistics.
Hossain MM; Chen Z
Pharm Stat; 2012; 11(3):267-8. PubMed ID: 22451454
[TBL] [Abstract][Full Text] [Related]
3. Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design.
Richert L; Doussau A; Lelièvre JD; Arnold V; Rieux V; Bouakane A; Lévy Y; Chêne G; Thiébaut R;
Trials; 2014 Feb; 15():68. PubMed ID: 24571662
[TBL] [Abstract][Full Text] [Related]
4. Application of Bayesian hierarchical models for phase I/II clinical trials in oncology.
Yada S; Hamada C
Pharm Stat; 2017 Mar; 16(2):114-121. PubMed ID: 27892650
[TBL] [Abstract][Full Text] [Related]
5. A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials.
Xie F; Ji Y; Tremmel L
Contemp Clin Trials; 2012 Jul; 33(4):739-48. PubMed ID: 22426247
[TBL] [Abstract][Full Text] [Related]
6. A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials.
Wason JM; Trippa L
Stat Med; 2014 Jun; 33(13):2206-21. PubMed ID: 24421053
[TBL] [Abstract][Full Text] [Related]
7. SPIRIT: A seamless phase I/II randomized design for immunotherapy trials.
Guo B; Li D; Yuan Y
Pharm Stat; 2018 Sep; 17(5):527-540. PubMed ID: 29882388
[TBL] [Abstract][Full Text] [Related]
8. Biomarker-based Bayesian randomized phase II clinical trial design to identify a sensitive patient subpopulation.
Morita S; Yamamoto H; Sugitani Y
Stat Med; 2014 Oct; 33(23):4008-16. PubMed ID: 24820639
[TBL] [Abstract][Full Text] [Related]
9. Seamlessly expanding a randomized phase II trial to phase III.
Inoue LY; Thall PF; Berry DA
Biometrics; 2002 Dec; 58(4):823-31. PubMed ID: 12495136
[TBL] [Abstract][Full Text] [Related]
10. Design issues in randomized phase II/III trials.
Korn EL; Freidlin B; Abrams JS; Halabi S
J Clin Oncol; 2012 Feb; 30(6):667-71. PubMed ID: 22271475
[TBL] [Abstract][Full Text] [Related]
11. A Bayesian response-adaptive covariate-balanced randomization design with application to a leukemia clinical trial.
Yuan Y; Huang X; Liu S
Stat Med; 2011 May; 30(11):1218-29. PubMed ID: 21432894
[TBL] [Abstract][Full Text] [Related]
12. A hierarchical Bayesian design for randomized Phase II clinical trials with multiple groups.
Yin J; Qin R; Sargent DJ; Erlichman C; Shi Q
J Biopharm Stat; 2018; 28(3):451-462. PubMed ID: 28448747
[TBL] [Abstract][Full Text] [Related]
13. General keynote: clinical trial design.
Berry DA
Gynecol Oncol; 2003 Jan; 88(1 Pt 2):S114-6; S122-3. PubMed ID: 12586099
[No Abstract] [Full Text] [Related]
14. The inclusion of real world evidence in clinical development planning.
Martina R; Jenkins D; Bujkiewicz S; Dequen P; Abrams K;
Trials; 2018 Aug; 19(1):468. PubMed ID: 30157904
[TBL] [Abstract][Full Text] [Related]
15. BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials.
Jiang L; Thall PF; Yan F; Kopetz S; Yuan Y
Clin Trials; 2023 Oct; 20(5):486-496. PubMed ID: 37313712
[TBL] [Abstract][Full Text] [Related]
16. Practical Bayesian guidelines for phase IIB clinical trials.
Thall PF; Simon R
Biometrics; 1994 Jun; 50(2):337-49. PubMed ID: 7980801
[TBL] [Abstract][Full Text] [Related]
17. Optimal two-stage randomized phase II clinical trials.
Logan BR
Clin Trials; 2005; 2(1):5-12. PubMed ID: 16279574
[TBL] [Abstract][Full Text] [Related]
18. A Bayesian adaptive phase II clinical trial design accounting for spatial variation.
Guo B; Zang Y
Stat Methods Med Res; 2019; 28(10-11):3187-3204. PubMed ID: 30229695
[TBL] [Abstract][Full Text] [Related]
19. New designs for the selection of treatments to be tested in randomized clinical trials.
Simon R; Thall PF; Ellenberg SS
Stat Med; 1994 Mar 15-Apr 15; 13(5-7):417-29. PubMed ID: 8023026
[TBL] [Abstract][Full Text] [Related]
20. A randomized two-stage design for phase II clinical trials based on a Bayesian predictive approach.
Cellamare M; Sambucini V
Stat Med; 2015 Mar; 34(6):1059-78. PubMed ID: 25545805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
